Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bevacizumab + MEDI3617|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 11 VEGFR Inhibitor (Pan) 32||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|MEDI3617||MEDI3617 is an human monoclonal antibody that prevents the binding of angiopoietin 2 to the Tie2 receptor in vitro, and inhibits angiogenesis and tumor growth in vivo (PMID: 22327175, PMID: 29559563).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||malignant glioma||not applicable||Bevacizumab + MEDI3617||Phase I||Actionable||In a Phase I trial, MEDI3617 in combination with Avastin (bevacizumab) resulted in no objective response (0/11) and stable disease in 18% (2/11) of patients with recurrent malignant glioma, with a median progression-free survival of 1.4 months (PMID: 29559563; NCT01248949).||29559563|
|Unknown unknown||Advanced Solid Tumor||not applicable||Bevacizumab + MEDI3617||Phase I||Actionable||In a Phase I trial, MEDI3617 in combination with Avastin (bevacizumab) resulted in objective response (OS) in 7% (2/27) and stable disease (SD) in 37% (10/27) of patients with advanced solid tumors, with a median progression-free survival (mPFS) of 2.0 months in the Q2W (treatment every 2 weeks) arm, and OS in 6% (1/16), SD in 69% (11/16) of patients with a mPFS of 11.4 months in the Q3W arm (PMID: 29559563; NCT01248949).||29559563|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|